Rain Enhancement Stock Price, News & Analysis

Rain Therapeutics Inc. (NasdaqGS: RAIN), a biotechnology firm focused on precision oncology, will announce its third-quarter financial results for the period ending September 30, 2022, on November 10, 2022. The report will include updates on its lead product candidate, milademetan, an oral inhibitor targeting the MDM2-p53 complex. A conference call is scheduled for 2:00 PM PT (5:00 PM ET) on the same day to discuss the results and business developments.

Rain Therapeutics Inc. (NasdaqGS: RAIN) presented a poster on milademetan, a small molecule inhibitor targeting the MDM2-p53 complex, at the 34th EORTC/AACR/NCI Symposium in Barcelona on October 26, 2022. The presentation titled "Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53" was led by Dr. Vijaya G. Tirunagaru. Rain Therapeutics focuses on precision oncology, utilizing a genetically-based patient selection strategy for its therapies, including milademetan, which reactivates the p53 protein.

Rain Therapeutics (NasdaqGS: RAIN) has announced its participation in Citi’s 17th Annual BioPharma Conference, scheduled for September 7-8, 2022, at the Four Seasons Hotel, Boston, MA. CEO Avanish Vellanki will be part of a targeted oncology panel on September 8 from 2:40-3:25 PM ET. The company focuses on developing precision oncology therapies, including milademetan, a small molecule inhibitor of the MDM2-p53 complex, which reactivates p53. Rain emphasizes a tumor-agnostic strategy to select patients based on genetic profiles.

Rain Therapeutics Inc. (NASDAQ: RAIN) reported a net loss of $17.6 million for Q2 2022, increasing from $8.2 million in Q2 2021. For the six months ended June 30, 2022, losses totaled $35 million, up from $15 million in the prior year. The company's cash position stands at $105.7 million, providing sufficient runway into mid-2024. Notably, the Phase 3 MANTRA trial completed enrollment five months early, with topline data expected in H1 2023. Ongoing clinical trials, including MANTRA-2 and anticipated MANTRA-3, show a strong pipeline for the milademetan program.

Rain Therapeutics has successfully completed enrollment for its Phase 3 MANTRA trial, five months ahead of schedule, with 175 patients recruited for the study of milademetan. This trial targets patients with well-differentiated/dedifferentiated liposarcoma who have progressed on prior therapies. The primary endpoint is progression-free survival, with topline data expected in the first half of 2023. Milademetan is positioned as a novel therapy aiming to reactivate p53 and has shown promise in earlier trials.

Rain Therapeutics has completed enrollment in its Phase 3 MANTRA trial for milademetan, an oral MDM2-p53 complex inhibitor, achieving this milestone five months ahead of schedule. The trial involved 175 patients with well-differentiated/dedifferentiated liposarcoma (WD/DD LPS) and aims to show a doubling of progression-free survival compared to the standard of care. Topline data is expected in the first half of 2023. Rain anticipates additional trials for milademetan targeting various cancers, with the drug already having received orphan drug designation from the FDA.

Rain Therapeutics Inc. (NASDAQ: RAIN) will announce its Q2 financial results on August 4, 2022, at 2:00 PM PT. The company is focused on precision oncology therapeutics, particularly its lead candidate, milademetan, which targets oncogenic drivers. The announcement will include a conference call to discuss financial results and recent progress. Investors can access a replay via the company’s website afterwards. Rain Therapeutics is committed to genetically selecting patients for its therapies, enhancing treatment specificity in cancer care.

Rain Therapeutics (NasdaqGS: RAIN) announced three poster presentations at the 2022 ASCO Annual Meeting, focusing on their oral MDM2 inhibitor, milademetan. The presentations will cover:

• Using CDKN2A loss to predict sensitivity (Abstract 3136)
• MANTRA: A phase 3 study of milademetan vs. trabectedin in dedifferentiated liposarcomas (Abstract TPS11589)
• MANTRA-2: A phase 2 study in TP53-wild type tumors (Abstract TPS3165)

All posters will be available on the Rain website following the event.

Rain Therapeutics Inc. (NASDAQ: RAIN) announced its Q1 2022 results, reporting a net loss of $17.4 million compared to $6.8 million in the same quarter last year. The company has a cash position of $123.2 million, providing a runway into the first half of 2024 for its clinical programs. Key updates include earlier-than-expected topline data from the Phase 3 MANTRA trial for liposarcoma slated for H1 2023 and planned commencement of Phase 2 trials MANTRA-3 and MANTRA-4 in Q4 2022. Research and development expenses rose to $13.6 million, largely due to ongoing trials.